Glibenclamide API Manufacturers

compare suppliers & get competitive offers

Filters

Reset current filters

Type
Production region
Qualifications
Country of origin

Producer

Produced in:

India

Established in: 2021

MOQ: -

Employees: 19

API, Intermediates, Building Blocks, Impurities, Amino acids and Peptides

Small quantity APIs to commercial scale

GMP and USFDA certification based on quantity, order, assignment.

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • GMP

  • CoA

  • FDA

Located in:

France

Producer

Produced in:

France

MOQ: -

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • CEP

  • coa

  • GMP

  • FDA

Located in:

India

Produced in:

India

MOQ: -

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • coa

Located in:

Italy

Producer

Produced in:

United States

MOQ: -

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • GMP

  • CoA

Located in:

India

Produced in:

India

MOQ: -

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • CEP

  • WC

  • coa

Located in:

India

Producer

Produced in:

India

MOQ: -

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • coa

  • CEP

  • GMP

  • FDA

Contact supplier

Replies slower than most

Produced in:

Unknown

Established in: 1963

MOQ: -

Employees: 800+

World’s 1st exclusive API distributor

Portfolio of 600+ APIs

>250 clients in Europe

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • CoA

  • MSDS

  • GMP

Located in:

India

Produced in:

India

MOQ: -

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • CoA

  • DMF

Located in:

Italy

Producer

Produced in:

Italy

MOQ: -

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • coa

  • CEP

  • GMP

  • FDA

Located in:

Italy

Producer

Produced in:

Italy

MOQ: -

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • DMF

  • GMP

  • coa

Located in:

France

Producer

Produced in:

Unknown

MOQ: -

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • CEP

  • GMP

  • CoA

How does it work?

1
Register for free
icon

You can register for free as long as you are registering on behalf of a legal company related to the pharmaceutical industry

2
Start sourcing
icon

Search in the search bar the product that you’re looking for. We’ll show you an overview of all available suppliers. Use the filters to select the relevant suppliers only

3
Send inquiries
icon

Have you found interesting suppliers? Then it’s time to contact them. Use the send inquiry button and send them a message. You can send for each product, 3 inquiries per week

4
Get quotation
icon

Suppliers get notified by Pharmaoffer that they’ve received a new inquiry. They will come back to you with their questions, certificates, and offer in the chat on Pharmaoffer. We will send you an email in case of any news

5
Arrange agreement
icon

Does the supplier meet your quality and commercial requirements? Then you can place the order. Just follow the steps of our order module

Looking for Glibenclamide API 10238-21-8?

Description:
Here you will find a list of producers, manufacturers and distributors of Glibenclamide. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
API | Excipient name:
Glibenclamide 
Synonyms:
glyburide  
Cas Number:
10238-21-8 

Glibenclamide is a type of Sulfonylureas


Sulfonylureas belong to a subcategory of pharmaceutical active ingredients known as antidiabetic agents. These compounds play a crucial role in managing type 2 diabetes, a metabolic disorder characterized by high blood sugar levels. Sulfonylureas work by stimulating the pancreas to produce more insulin, a hormone responsible for regulating blood glucose levels.

As pharmaceutical API, sulfonylureas are highly effective in lowering blood sugar levels by promoting insulin secretion and increasing the sensitivity of cells to insulin. This mechanism of action makes them valuable in the treatment of type 2 diabetes, especially when other measures such as diet and exercise have proven inadequate.

Sulfonylureas are widely prescribed due to their proven efficacy, oral administration convenience, and cost-effectiveness. They are available in various formulations, including tablets and extended-release formulations, allowing flexibility in dosing regimens. Additionally, their long-established presence in the market has resulted in a comprehensive understanding of their safety profile and potential side effects.

Some common sulfonylurea drugs include glipizide, glimepiride, and gliclazide. These compounds are often prescribed as part of a comprehensive treatment plan for type 2 diabetes, along with lifestyle modifications and other antidiabetic medications.

It is important to note that the use of sulfonylureas should be carefully monitored by healthcare professionals to ensure optimal blood sugar control and to minimize the risk of hypoglycemia, a potential side effect. Patients taking sulfonylureas should also be educated about the importance of regular blood glucose monitoring and adhering to prescribed dosages.

In conclusion, sulfonylureas represent an essential subcategory of pharmaceutical APIs used in the treatment of type 2 diabetes. Their mechanism of action, proven efficacy, and cost-effectiveness make them a valuable tool in managing this chronic metabolic condition. Healthcare professionals play a vital role in guiding the appropriate use of sulfonylureas to optimize patient outcomes and ensure safety.


Glibenclamide (Sulfonylureas), classified under Anti-diabetics


Anti-diabetics, belonging to the pharmaceutical API (Active Pharmaceutical Ingredient) category, are a group of compounds designed to manage and treat diabetes mellitus, a chronic metabolic disorder characterized by high blood sugar levels. These medications play a vital role in controlling diabetes and preventing complications associated with the disease.

Anti-diabetics encompass a wide range of drug classes, including biguanides, sulfonylureas, thiazolidinediones, dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and glucagon-like peptide-1 (GLP-1) receptor agonists. Each class works through different mechanisms to regulate blood sugar levels and improve insulin sensitivity.

Biguanides, such as metformin, reduce glucose production by the liver and enhance insulin sensitivity in peripheral tissues. Sulfonylureas, like glipizide, stimulate insulin secretion from pancreatic beta cells. Thiazolidinediones, including pioglitazone, improve insulin sensitivity in muscle and adipose tissues. DPP-4 inhibitors, such as sitagliptin, increase insulin release and inhibit glucagon secretion. SGLT2 inhibitors, like dapagliflozin, decrease renal glucose reabsorption, leading to increased urinary glucose excretion. GLP-1 receptor agonists, such as exenatide, enhance insulin secretion, suppress glucagon release, slow gastric emptying, and promote satiety.

These anti-diabetic APIs serve as the foundational ingredients for the formulation of various oral tablets, capsules, and injectable medications used in the treatment of diabetes. By targeting different aspects of glucose regulation, they help patients achieve and maintain optimal blood sugar levels, thus reducing the risk of diabetic complications, such as cardiovascular disease, neuropathy, and nephropathy.

It is crucial for healthcare professionals to prescribe and administer these anti-diabetic medications appropriately, considering factors like the patient's medical history, co-existing conditions, and potential drug interactions. Regular monitoring of blood glucose levels and close medical supervision are necessary to ensure effective diabetes management.

In conclusion, anti-diabetics form a critical category of pharmaceutical APIs used for the treatment of diabetes. These compounds, encompassing various drug classes, work through distinct mechanisms to regulate blood sugar levels and improve insulin sensitivity. By facilitating glucose control, anti-diabetic APIs help mitigate the risk of complications associated with diabetes mellitus, ultimately promoting better health outcomes for patients.



Glibenclamide manufacturers | traders | suppliers

We have 11 companies offering Glibenclamide produced in 5 different countries.

Get in contact with the supplier of your choice:

  • SETV Global from India, product country of origin India
  • Orgapharm from France, product country of origin France
  • Unnati Pharmaceuticals Pvt Ltd from India, product country of origin India
  • Cambrex from Italy, product country of origin United States
  • Elixir Pharma from India, product country of origin India
  • USV from India, product country of origin India
  • TIEFENBACHER API + Ingredients from Germany, product country of origin Unknown
  • Auro Laboratories from India, product country of origin India
  • Lusochimica from Italy, product country of origin Italy
  • ICROM from Italy, product country of origin Italy
  • Sanofi from France, product country of origin Unknown

Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.

You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.